

Financial news for NERV dated on 2020-06-08: 10 Biggest Price Target Changes For Monday

Financial news for NERV dated on 2020-06-08: HC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to \$10

Financial news for NERV dated on 2020-06-05: Hearing JMP Securities is Reinstating its Market Outperform Rating on Minerva Neurosciences with a \$9 Price Target

Financial news for NERV dated on 2020-06-02: 71 Biggest Movers From Yesterday

Financial news for NERV dated on 2020-06-01: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for NERV dated on 2020-06-01: Mid-Morning Market Update: Markets Edge Higher; Zynga To Buy Mobile Game Developer Peak For \$1.8B

Financial news for NERV dated on 2020-06-01: 26 Stocks Moving in Monday's Pre-Market Session

Financial news for NERV dated on 2020-06-01: 72 Biggest Movers From Friday

Financial news for NERV dated on 2020-05-29: Mid-Afternoon Market Update: U.S. Stocks Turn Positive; Crude Oil Surges Over 5%

Financial news for NERV dated on 2020-05-29: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for NERV dated on 2020-05-29: Mid-Day Market Update: Canopy Growth Slides After Q4 Results; Sonoma Pharmaceuticals Shares Surge

Financial news for NERV dated on 2020-05-29: Minerva Shares Halted On Third Circuit Breaker Of The Day, Stock Down 81.2% For Session

Financial news for NERV dated on 2020-05-29: Mid-Morning Market Update: Markets Open Lower; Big Lots Beats Q1 Estimates

Financial news for NERV dated on 2020-05-29: Minerva Shares Resumed Trade, Fall 67%, Halted On Circuit Breaker

Financial news for NERV dated on 2020-05-29: UPDATE: Minerva Schizophrenia Phase 3 Did Not Meet Primary Endpoint

Financial news for NERV dated on 2020-05-29: Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia; Shares Still Halted

Financial news for NERV dated on 2020-05-29: Minerva Neurosciences Halted Due To News Pending

Financial news for NERV dated on 2020-05-28: Minerva Neurosciences Option Alert: Jul 17 \$22.5 Calls at the Ask: 2939 @ \$4.0 vs 40 OI; Ref=\$13.585

Financial news for NERV dated on 2020-05-28: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for NERV dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for NERV dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NERV dated on 2020-05-22: Stocks That Hit 52-Week Highs On Friday

Financial news for NERV dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for NERV dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for NERV dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for NERV dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for NERV dated on 2020-05-13: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NERV dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for NERV dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NERV dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for NERV dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for NERV dated on 2020-05-08: Stocks That Hit 52-Week Highs On Friday

Financial news for NERV dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for NERV dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for NERV dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NERV dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for NERV dated on 2020-05-04: Stocks That Hit 52-Week Highs On Monday

Financial news for NERV dated on 2020-05-04: Minerva Neurosciences Q1 EPS \$(0.310) Beats \$(0.360) Estimate

Financial news for NERV dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for NERV dated on 2020-03-13: 136 Biggest Movers From Yesterday

Financial news for NERV dated on 2020-03-12: 90 Stocks Moving In Thursday's Mid-Day Session

Financial news for NERV dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for NERV dated on 2020-03-12: Mid-Day Market Update: Crude Oil Down Over 5%; Alpha Pro Tech Shares Spike Higher

Financial news for NERV dated on 2020-03-12: Mid-Morning Market Update: Markets Open Lower After Trump Bans Travel From Europe

Financial news for NERV dated on 2020-03-09: Minerva Neurosciences Q4 EPS \$(0.77) Down From \$(0.34) YoY

Financial news for NERV dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for NERV dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for NERV dated on 2020-02-19: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NERV dated on 2020-02-05: Minerva Neurosciences Reports Completion Of Patient Enrollment In Phase 3 Trial Of Roluperidone For Treatment Of Negative Symptoms In Schizophrenia

Financial news for NERV dated on 2020-01-27: Minerva Neurosciences Option Alert: Jul 17 \$12.5 Calls at the Ask: 2980 @ \$4.1 vs 191 OI; Earnings 3/10 Before Open [est] Ref=\$8.05

Financial news for NERV dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for NERV dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for NERV dated on 2020-01-17: 76 Biggest Movers From Yesterday

Financial news for NERV dated on 2020-01-06: Minerva Neurosciences Says it Expects to Complete Enrollment for its Phase 3 Trial of Roluperidone in January

Financial news for NERV dated on 2019-12-26: 51 Biggest Movers From Tuesday

Financial news for NERV dated on 2019-12-24: 78 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-12-23: 60 Biggest Movers From Friday

Financial news for NERV dated on 2019-12-20: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for NERV dated on 2019-12-20: 68 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-12-19: Mid-Afternoon Market Update: Rite Aid Jumps On Upbeat Earnings; Apogee Enterprises Shares Slide

Financial news for NERV dated on 2019-12-19: 46 Stocks Moving In Thursday's Mid-Day Session

Financial news for NERV dated on 2019-12-19: Mid-Day Market Update: Dow Rises Over 100 Points; Minerva Neurosciences Shares Plunge

Financial news for NERV dated on 2019-12-19: JMP Securities Maintains Market Outperform on Minerva Neurosciences, Lowers Price Target to \$18

Financial news for NERV dated on 2019-12-19: Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial

Financial news for NERV dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for NERV dated on 2019-12-19: 28 Stocks Moving in Thursday's Pre-Market Session

Financial news for NERV dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for NERV dated on 2019-12-19: H.C. Wainwright Reiterates Buy on Minerva Neurosciences, Lowers Price Target to \$20

Financial news for NERV dated on 2019-12-18: Minerva Shares To Resume Trade At 4:35 p.m. EST

Financial news for NERV dated on 2019-12-18: Minerva Neurosciences Announces Phase 2b Trial Of MIN-117 In Major Depressive Disorder Did Not Meet Primary And Key Secondary Endpoints; Says Has No Plans For Further Clinical Development In MDD

Financial news for NERV dated on 2019-12-18: Minerva Biosciences Shares Halted News Pending

Financial news for NERV dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-12-09: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for NERV dated on 2019-11-20: 77 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-11-19: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NERV dated on 2019-11-04: Minerva Neurosciences Q3 EPS \$(0.36) Beats \$(0.37) Estimate

Financial news for NERV dated on 2019-10-31: 27 Stocks Moving In Thursday's Mid-Day Session

Financial news for NERV dated on 2019-10-21: Stocks That Hit 52-Week Lows On Monday

Financial news for NERV dated on 2019-10-03: 46 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-10-02: 52 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-10-01: Mid-Afternoon Market Update: Crude Oil Down Over 1%; Roan Resources Shares Jump

Financial news for NERV dated on 2019-10-01: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NERV dated on 2019-10-01: Mid-Day Market Update: Dow Falls Over 200 Points; Constellation Pharmaceuticals Shares Spike Higher

Financial news for NERV dated on 2019-10-01: Mid-Morning Market Update: Markets Open Lower; McCormick Earnings Top Expectations

Financial news for NERV dated on 2019-10-01: Minerva Neurosciences shares are trading lower after the company delayed the results for its Schizophrenia drug.

Financial news for NERV dated on 2019-10-01: 23 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for NERV dated on 2019-10-01: Minerva Neurosciences Announces 384 Patients Of A Total Target Of 501 Have Been Enrolled In Phase 3 Trial Of Roluperidone; Anticipates Top-Line Results To Be Available In 1H 2020

Financial news for NERV dated on 2019-09-25: Benzinga's Top Upgrades, Downgrades For September 25, 2019

Financial news for NERV dated on 2019-09-25: Chardan Capital Initiates Coverage On Minerva Neurosciences with Buy Rating, Announces \$17 Price Target

Financial news for NERV dated on 2019-09-24: Catalent And Minerva Neurosciences Enter Commercial Supply Agreement For Schizophrenia Drug Roluperidone

Financial news for NERV dated on 2019-09-18: Benzinga's Top Upgrades, Downgrades For September 18, 2019

Financial news for NERV dated on 2019-09-18: William Blair Initiates Coverage On Minerva Neurosciences with Outperform Rating

Financial news for NERV dated on 2019-09-12: 71 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-09-09: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for NERV dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for NERV dated on 2019-08-06: 70 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-08-05: Minerva Neurosciences Q2 EPS \$(0.32) Beats \$(0.42) Estimate

Financial news for NERV dated on 2019-07-05: 48 Biggest Movers From Wednesday

Financial news for NERV dated on 2019-06-26: 51 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-06-25: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NERV dated on 2019-06-25: A Look At Benzinga Pro's Most-Searched Tickers For June 25, 2019

Financial news for NERV dated on 2019-06-25: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, June 25 2019

Financial news for NERV dated on 2019-06-25: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NERV dated on 2019-06-25: 60 Biggest Movers From Yesterday

Financial news for NERV dated on 2019-06-24: Mid-Afternoon Market Update: Crude Oil Up 1%; Minerva Neurosciences Shares Spike Higher

Financial news for NERV dated on 2019-06-24: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for NERV dated on 2019-06-24: Mid-Day Market Update: PCM Jumps Following Acquisition News; 360 Finance Shares Slide

Financial news for NERV dated on 2019-06-24: Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial

Financial news for NERV dated on 2019-06-24: Mid-Morning Market Update: Markets Edge Higher; Eldorado To Buy Caesars For \$17.3B

Financial news for NERV dated on 2019-06-24: Minerva Neurosciences shares are trading higher after the company announced that its Phase 2B trial for the clinical trial of Seltorexant achieved its primary and key secondary objectives.

Financial news for NERV dated on 2019-06-24: Minerva Neurosciences and Del Frisco's to Resume Trading at 8:00am ET

Financial news for NERV dated on 2019-06-24: Minerva Neurosciences Cmn Shares To Resume Trade At 8:00 a.m. EDT

Financial news for NERV dated on 2019-06-24: Minerva Neurosciences Achieves Primary and Key Secondary Objectives in its Phase 2B Clinical Trial of Seltorexant

Financial news for NERV dated on 2019-06-24: Minerva Neurosciences Halted, News Pending

Financial news for NERV dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for NERV dated on 2019-06-18: The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

Financial news for NERV dated on 2019-06-13: The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetrphase Downsizes

Financial news for NERV dated on 2019-06-12: The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for NERV dated on 2019-05-31: Benzinga's Top Upgrades, Downgrades For May 31, 2019

Financial news for NERV dated on 2019-05-31: H.C. Wainwright Initiates Coverage On Minerva Neurosciences with Buy Rating, Announces \$22 Price Target

Financial news for NERV dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for NERV dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for NERV dated on 2019-05-23: The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

Financial news for NERV dated on 2019-05-13: Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug

Financial news for NERV dated on 2019-05-13: Minerva Neurosciences Announces 'Positive' Top Line Results in Phase 2b Clinical Trial With Seltorexant in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs

Financial news for NERV dated on 2019-04-11: Minerva Neurosciences Highlights Presentation Pre-Clinical Data Suggesting A Mechanistic Role Of Roluperidone In Addressing Negative Symptoms Of Schizophrenia

Financial news for NERV dated on 2019-03-12: Minerva Neurosciences, Inc Q4 EPS \$(0.34) Beats \$(0.36) Estimate

Financial news for NERV dated on 2019-03-12: Earnings Scheduled For March 12, 2019

Financial news for NERV dated on 2019-03-06: Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.

Financial news for NERV dated on 2018-11-28: Minerva Neurosciences Announces New Patent Application For MIN-117 Related To Broad Effect On Pain

Financial news for NERV dated on 2018-11-19: Minerva Neurosciences Announces Results Of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered At Supra-Therapeutic Doses In Healthy Volunteers; Says Doses Up To 256 Miligrams Appear Safe And Will Tolerated

Financial news for NERV dated on 2018-11-05: Minerva Neurosciences, Inc - Common Stock Q3 EPS \$(0.31) Beats \$(0.38) Estimate

Financial news for NERV dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for NERV dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for NERV dated on 2018-09-25: Stocks Which Set New 52-Week High Yesterday, September 24th

Financial news for NERV dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver

Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for NERV dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for NERV dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for NERV dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for NERV dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for NERV dated on 2018-08-24: Stocks Which Set New 52-Week High Yesterday, August 23rd

Financial news for NERV dated on 2018-08-23: Stocks Which Set New 52-Week High Yesterday, August 22nd

Financial news for NERV dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for NERV dated on 2018-08-22: Minerva Neurosciences Reports Findings From Recent Pre-Clinical Study Which Provided Evidence Of Effect Of MIN-101 On Brain-Derived Neurotrophic Factor

Financial news for NERV dated on 2018-08-02: Minerva Neurosciences Q2 EPS \$(0.32) Beats \$(0.38) Estimate

Financial news for NERV dated on 2018-07-17: Minerva Neurosciences Elects Jeryl Hilleman To Board Of Directors

Financial news for NERV dated on 2018-05-18: 48 Biggest Movers From Yesterday

Financial news for NERV dated on 2018-05-17: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for NERV dated on 2018-05-17: Minerva Neurosciences Shares Up 17.7% Premarket After Journal of Clinical Psychiatry Published Positive Results Of Cognitive Performance From Phase 2B Trial Of Roluperidone In Schizophrenia Patients

Financial news for NERV dated on 2018-05-17: Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia

Financial news for NERV dated on 2018-05-03: Minerva Neurosciences, Inc - Common Stock Q1 EPS \$(0.32) Misses \$(0.28) Estimate

Financial news for NERV dated on 2018-04-09: Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder

Financial news for NERV dated on 2018-03-12: Minerva Neurosciences Reports Q4 EPS \$0.00 vs \$(0.38) Est., No Sales

Financial news for NERV dated on 2018-03-12: Earnings Scheduled For March 12, 2018

Financial news for NERV dated on 2018-02-21: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NERV dated on 2017-12-21: Minerva Neurosciences Reports Enrollment Of First Patient In Phase 2b Trial Comparing MIN-202 vs Quetiapine

Financial news for NERV dated on 2017-12-21: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant Versus Quetiapine

Financial news for NERV dated on 2017-12-19: Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

Financial news for NERV dated on 2017-12-11: Minerva Neurosciences Names Richard Russell Pres

Financial news for NERV dated on 2017-12-06: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant in Patients With Insomnia Disorder

Financial news for NERV dated on 2017-11-06: Minerva Neurosciences Reports Q3 EPS \$(0.28) vs \$(0.27) Est.

Financial news for NERV dated on 2017-09-05: Minerva Neurosciences Reports Enrollment Of Initial Patient In Phase 2B Trial Of MIN-202

Financial news for NERV dated on 2017-09-01: 18 Biggest Mid-Day Gainers For Friday

Financial news for NERV dated on 2017-09-01: Benzinga's Top Upgrades, Downgrades For September 1, 2017

Financial news for NERV dated on 2017-08-25: Minerva Neurosciences Reports European Commission Approval Of Amendment Of MIN-202 Agreement With Janssen

Financial news for NERV dated on 2017-08-03: Minerva Neurosciences Reports Q2 EPS \$(0.27) vs \$(0.34) Est.

Financial news for NERV dated on 2017-06-27: Minerva Neurosciences To Offer 5M Shares Common Stock

Financial news for NERV dated on 2017-05-04: Minerva Neurosciences Q1 EPS \$(0.30) vs \$(0.30) Est, No Sales

Financial news for NERV dated on 2017-03-21: Minerva Neurosciences Announces Institutional Investors Have Exercised Warrants With Respect To 1.6M Shares At Price Of \$5.772/Share Since 12/31/16; Warrants Have Now Expired

Financial news for NERV dated on 2017-03-21: Minerva Neurosciences Reports Certain Investors in March 2015 Private Placement Exercised Warrants; Gross Proceeds to Co of ~\$8.2M

Financial news for NERV dated on 2017-03-13: Minerva Neurosciences Reports Q4 EPS \$(0.27) vs \$(0.25) Est.

Financial news for NERV dated on 2017-03-06: 15 Biggest Mid-Day Gainers For Monday

Financial news for NERV dated on 2017-03-06: Benzinga's Top Upgrades, Downgrades For March 6, 2017

Financial news for NERV dated on 2017-03-06: Jefferies Initiates Coverage On Minerva Neurosciences With Buy, Announces \$17 Price Target

Financial news for NERV dated on 2017-01-20: Minerva Neurosciences Reports Added Data Analyses from Phase IIb Trial of MIN-101 in Schizophrenia Highlight Benefit in Multiple Measurements of Cognitive Function

Financial news for NERV dated on 2016-12-20: Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer

Financial news for NERV dated on 2016-11-17: Jefferies London Health Care Conference Continues Today

Financial news for NERV dated on 2016-11-03: Minerva Neurosciences Q3 EPS \$(0.24) vs \$(0.21) Est, No Revenue

Financial news for NERV dated on 2016-11-03: Minerva Neurosciences Reports Q3 EPS \$(0.24) vs. Est. \$(0.21)

Financial news for NERV dated on 2016-10-27: 15 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for NERV dated on 2016-10-26: Minerva Reports Positive Data from Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia: 'Data show continuous improvement in negative symptoms, stable positive symptoms and extended safety profile'

Financial news for NERV dated on 2016-10-13: Minerva Neurosciences Reports Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting

Financial news for NERV dated on 2016-09-27: Index Venture Associates Report 7.3% Stake In Minerva Neurosciences

Financial news for NERV dated on 2016-09-26: UPDATE: Minerva Reports FDA Acceptance of IND for MIN-117, Last Patient Completed Extension Phase of Phase IIb Trial of MIN-101

Financial news for NERV dated on 2016-09-26: Minerva Neurosciences Reports Update on MIN-101, MIN-117 Programs

Financial news for NERV dated on 2016-08-10: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NERV dated on 2016-08-04: Minerva Neurosciences Reports Q2 EPS \$(0.18) vs. Est. \$(0.30)

Financial news for NERV dated on 2016-06-21: Director Kupfer Buys 55,635 Shares of Minerva Neurosciences @ \$10.84/Share -Form 4

Financial news for NERV dated on 2016-06-14: Minerva Neurosciences Prices 5.263M Shares At \$9.50/Share

Financial news for NERV dated on 2016-06-13: Minerva Neurosciences Reports Proposed Public Offering of Common Stock

Financial news for NERV dated on 2016-06-01: Minerva Neurosciences Continues To Rally, Up 300% In A Week

Financial news for NERV dated on 2016-05-27: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for NERV dated on 2016-05-26: Mid-Afternoon Market Update: Abercrombie & Fitch Slides On Disappointing Results; Minerva Neurosciences Shares Spike Higher

Financial news for NERV dated on 2016-05-26: Minverva Biosciences Surrenders Some Of Earlier Gains

Financial news for NERV dated on 2016-05-26: Mid-Day Market Update: Dollar Tree Surges Following Earnings Beat; OvaScience Shares Drop

Financial news for NERV dated on 2016-05-26: Minerva Neurosciences Shares Jump 200% On Positive Results From Phase IIB Study of MIN-101 Monotherapy

Financial news for NERV dated on 2016-05-26: Mid-Morning Market Update: Markets Mostly Flat; Dollar General Profit Beats Expectations

Financial news for NERV dated on 2016-05-26: Minerva Neurosciences Spikes to High of \$10.38 Following MIN-117 Results

Financial news for NERV dated on 2016-05-26: Minerva Neurosciences Shares Spiking Higher

Financial news for NERV dated on 2016-05-26: Minerva Neurosciences To Resume Trade At 8:45am ET

Financial news for NERV dated on 2016-05-26: UPDATE: Minerva Neurosciences Says No Unexpected Adverse Events Were Reported, MIN-117 Not Associated With Cognitive Impairment, Sexual Dysfunction, Suicidal Ideation Or Weight Gain

Financial news for NERV dated on 2016-05-26: UPDATE: Minerva on MIN-117 Trial Reports 'Reduction in depressive symptoms demonstrated,' 'Good tolerability and safety profile observed,' 'Positive effect on sleep architecture shown'

Financial news for NERV dated on 2016-05-26: Minerva Reports Results in Phase IIA Trial of MIN-117: Meets Both Primary, Secondary Endpoints

Financial news for NERV dated on 2016-05-26: Minerva Neurosciences Min-101 Monotherapy Showed Statistically Significant Benefits Over Placebo In Improving Negative Symptoms As Well As PANSS Psychopathology Subscale, BNSS Total Score and CGI-S & CGI-I

Financial news for NERV dated on 2016-05-26: MInerva Neurosciences Meets Primary, Secondary Endpoint In MIN-101 Monotherapy

Financial news for NERV dated on 2016-05-26: Minerva Neurosciences Shares Halted News Pending

Financial news for NERV dated on 2016-05-12: Jefferies Assumes Minerva Neurosciences at Buy, Announces \$10.00 PT

Financial news for NERV dated on 2016-05-03: Minerva Neurosciences Reports Q1 EPS \$(0.29) vs. Est. \$(0.33)

Financial news for NERV dated on 2016-03-18: Minerva Neurosciences To Sell Dr. David Kupfer 181,488 Shares At \$5.51/Share

Financial news for NERV dated on 2016-03-14: Minerva Neurosciences Reports Q4 EPS \$(0.34) vs. (0.31)



Financial news for NERV dated on 2016-03-11: Minerva Neurosciences Announces Positive Topline Data From Phase 1B Clinical Trial With Min-202 For Major Depressive Disorder

Financial news for NERV dated on 2016-02-22: Minerva Reports Closing of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder

Financial news for NERV dated on 2016-02-01: Minerva Neurosciences MIN-202 Well-Tolerated in Phase I Clinical Study in Japanese Patients

Financial news for NERV dated on 2015-12-29: UPDATE: Minerva Says FDA Accepted IND App for MIN-101; Closed Enrollment for Phase IIb Trial of MIN-101

Financial news for NERV dated on 2015-12-29: Minerva Neurosciences Announces Update on MIN-101 Clinical Development Program

Financial news for NERV dated on 2015-12-18: Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101, Met 234 Patient Target

Financial news for NERV dated on 2015-12-09: Minerva Issues Year-End Update on Trials: Patient Enrollment Progress Confirms Timeline Expectations for Topline Data Availability from Four Trials in 1H'16

Financial news for NERV dated on 2015-11-05: Minerva Neurosciences Reports Q3 EPS \$(0.24) vs. Est. \$(0.36)

Financial news for NERV dated on 2015-09-24: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist

Financial news for NERV dated on 2015-08-05: Minerva Neurosciences Reports Q2 EPS \$(0.27) vs. Est. \$(0.41)

Financial news for NERV dated on 2015-07-21: Minerva Neurosciences Files for Up to \$150M Mixed Shelf

Financial news for NERV dated on 2015-06-16: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist

Financial news for NERV dated on 2015-05-18: Minerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors

Financial news for NERV dated on 2015-04-30: Minerva Neurosciences Files for Resale of 12.6M Shares by Selling Shareholders

Financial news for NERV dated on 2015-04-09: Federated Investors Shows 18.2% Stake in Minerva Neurosciences, Increased From 0.12%

Financial news for NERV dated on 2015-03-26: Minerva Neurosciences Reports Q4 EPS -\$0.40 Vs Est -\$0.46

Financial news for NERV dated on 2015-03-25: 13D Filing Shows Minerva Neurosciences Holder Care Capital Cuts Stake From 15.6% In December To 9% Now

Financial news for NERV dated on 2015-03-20: Minerva Neurosciences Director De Rubertis Buys 202,634 Shares @\$4.81/Share -Form 4

Financial news for NERV dated on 2015-03-13: Minerva Neurosciences Announces Offering Of 6.28M Shares For \$4.81/Share

Financial news for NERV dated on 2015-01-22: Morning Market Gainers

Financial news for NERV dated on 2015-01-22: Thursday's Morning Movers: Minerva, City National Pop 17% Higher

Financial news for NERV dated on 2015-01-21: Why Minerva Neurosciences Is Trading Higher

Financial news for NERV dated on 2015-01-21: Wednesday's After-Hours Movers: eBay Pops 2%, American Express Drops 2%

Financial news for NERV dated on 2015-01-21: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202

Financial news for NERV dated on 2015-01-20: Minerva Neurosciences Announces \$15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank

Financial news for NERV dated on 2015-01-06: Mid-Morning Market Update: Markets Open Higher; Commercial Metals Posts Upbeat Earnings

Financial news for NERV dated on 2015-01-06: Tuesday's Morning Market Movers: Minerva, El Pollo LoCo And More

Financial news for NERV dated on 2015-01-06: Stocks Hitting 52-Week Highs

Financial news for NERV dated on 2015-01-06: Morning Market Movers

Financial news for NERV dated on 2015-01-06: Minerva Neurosciences Soars 60% Following Parkinson's Disease Treatment News

Financial news for NERV dated on 2015-01-06: Benzinga's Top #PreMarket Gainers

Financial news for NERV dated on 2015-01-05: Monday's After-Hours Market Movers

Financial news for NERV dated on 2015-01-05: Minerva Neurosciences Announces Data Shows Analog of Minerva's MIN-301 Compound Improves Symptoms Of Parkinson's Disease in Primates

Financial news for NERV dated on 2014-11-25: Minerva Neurosciences Appoints Remy Luthringer As CEO

Financial news for NERV dated on 2014-09-22: rva Neurosciences Announces Completion Of FDA Review Of Investigational New Drug Application For MIN-202 And Plans For First U.S.-Based Clinical Trial

Financial news for NERV dated on 2014-07-28: Benzinga's Top Initiations

Financial news for NERV dated on 2014-07-28: JMP Securities Initiates Minerva Neurosciences At Market Perform, Shares Gain

Financial news for NERV dated on 2014-07-28: JMP Securities Initiates Coverage on Minerva Neurosciences, Inc. at Market Perform, Announces \$16.00 PT

Financial news for NERV dated on 2014-07-17: Shares of Minerva Neurosciences Moving Higher Following 13G Filing from J&J Showing 18% Stake in Co.

Financial news for NERV dated on 2014-07-14: Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer

Financial news for NERV dated on 2014-07-10: Minerva Shares Rise 22% on Heavy Insider Buying

Financial news for NERV dated on 2014-07-07: Stocks Hitting 52-Week Lows

Financial news for NERV dated on 2014-07-01: Hunting The Next GoPro: Short Week Brings Up To 7 IPOs

Financial news for NERV dated on 2014-07-01: Minerva Neurosciences Shares Open for Trade at \$6/Share, IPO Priced at \$6

Financial news for NERV dated on 2014-07-01: Waiting on 3 IPOs This Morning

Financial news for NERV dated on 2014-06-26: Waiting on 3 IPOs This Morning

Financial news for NERV dated on 2014-06-20: IPO Lookout: IPOs Up Double Digits On The Week